Immuno-Oncology Research Collaboration with iTeos Therapeutics

e-therapeutics plc announces that we have entered into a research collaboration agreement with iTeos Therapeutics, Inc ("iTeos", Nasdaq: ITOS). The collaboration will focus on the discovery of novel therapeutic approaches and targets in immuno-oncology.

Under the terms of the agreement, e-therapeutics will receive upfront and near-term cash payments material to the revenue of the Company. The Company is also eligible to receive undisclosed milestone payments through pre-clinical and clinical development, in addition to regulatory milestones per programme. e-therapeutics will remain free to explore additional collaborations in the space.

The collaboration will combine key expertise from both companies, including e-therapeutics' computational platform and iTeos' proprietary assays. iTeos is a leader in the immuno-oncology space developing next-generation therapies for patients with cancer. e-therapeutics' computational platform and in silico predictions have been experimentally validated across multiple therapeutic areas (including in immuno-oncology), demonstrating its ability to reproducibly assess millions of therapeutic hypotheses, gain insights into lesser-known mechanistic disease processes and identify therapeutic interventions with a higher probability of success than standard drug discovery processes. This translates into a more efficient drug discovery process with greater scope for novelty, as well as significant time and cost savings.

We are extremely pleased to partner with iTeos to help identify highly differentiated immuno-oncology medicines for patients. We believe that our computational platform can discover novel therapeutic approaches for iTeos to prosecute in a hugely promising area of cancer treatment. This collaboration provides further validation of the value of our network-driven, disease agnostic computational platform, which we will continue to leverage as we build our in-house RNAi based pipeline.

Ali Mortazavi

Chief Executive Officer